Corton Capital Inc. Viking Therapeutics, Inc. Transaction History

Corton Capital Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$17.4 - $94.5 $209,374 - $1.14 Million	-12,033 Reduced 79.63%	3,078 $252,000
Q4 2023 Feb 14, 2024	BUY	$9.24 - $19.64 $28,366 - $60,294	3,070 Added 25.5%	15,111 $281,000
Q3 2023 Nov 14, 2023	BUY	$10.92 - $16.0 $131,487 - $192,656	12,041 New	12,041 $133,000
Q2 2022 Aug 15, 2022	SELL	$2.11 - $3.15 $27,997 - $41,797	-13,269 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$3.0 - $4.88 $39,807 - $64,752	13,269 New	13,269 $40,000

480

66.2M

6.24M

3.01M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.83B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Corton Capital Inc., based on Form 13F filings with the SEC.

Stay updated on Corton Capital Inc. with notifications on news.